查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371877

到 2030 年血液疾病市场预测：按类型、疾病、治疗类型、配销通路和地区进行的全球分析

Blood Disorders Market Forecasts to 2030 - Global Analysis By Type (Hemophilia A, Hemophilia B, Von Willebrand Disease and Other Types), Disorder, Treatment Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球血液疾病市场规模为 150.8 亿美元，预计到 2030 年将达到 267.3 亿美元，预测期内年复合成长率为 8.6%。

血液疾病是一组影响血液及其成分的疾病。血液疾病也称为血液疾病或血液疾病。有些血液疾病从出生起就具有遗传性，而有些血液疾病则是由于多种要素导致的，包括感染疾病、自体免疫疾病和接触某些毒素。治疗选择包括药物和生活方式的改变以及更强化的治疗。

根据世界血友病联合会的报告，2017 年全球约有 315,423 人受到血液疾病的影响。其中，196,706 人患有血友病，76,144 人患有冯维勒布兰氏症 (VWD)，42,573 人患有其他血液疾病。

临床试验和研发增加

对临床试验和研究与开发的日益重视导致血液疾病的诊断和管理显着改善。更准确、更灵敏的血液疾病诊断测试的开发是研究和开发的结果。这些测试可以更快、更准确地鉴定，使医疗保健相关人员能够更早开始治疗患者。血液疾病临床试验、研发投资的增加以及患者预后的显着改善正在推动市场扩张。

缺乏标准化指导方针

血液疾病的复杂性和多样性、某些亚型研究的缺乏以及对个体化治疗策略的需求导致缺乏标准化建议。血液疾病的治疗通常需要血液学家、肿瘤学家、遗传学家和其他医疗保健专业人员之间的合作。这些不同专业人员之间的护理协调可能会导致治疗策略的改变。同时，资源限制和罕见疾病资料缺乏阻碍了市场扩张。

人们对血液疾病的认识不断提高

作为改善医疗保健系统和解决全球健康差距的更大措施的一部分，增加开发中国家对血液疾病的了解将改善这些疾病患者的健康和福祉，这是重要的一步。认识的提升为研究血液疾病和寻找治疗方法配合措施了更多的资金和关注。结果，用于研究和开发的资金不断增加，意识提升配合措施不断增加，市场需求不断增加。

报销政策不完善

血液疾病的治疗包括成本高昂的最先进治疗，如基因治疗和干细胞移植。血液疾病的治疗通常涉及多学科方法，其中包括血液学家、肿瘤学家、遗传学家和其他专家的意见。此外，市场规模有限、治疗计划复杂以及缺乏竞争等要素可能会限制政府和竞争性保险公司的预算并降低报销率。这些问题都阻碍了市场需求。

COVID-19 的影响

COVID-19 的疫情对血液疾病市场产生了重大影响。大流行导致常规医生预约和诊断测试的延误，导致血液疾病的诊断和治疗的延误。这场大流行扰乱了全球药品和医疗设备供应链，导致血液疾病基本药物的分配延迟和短缺。

预计预测期内血癌领域规模最大

血癌领域预计将出现良好的成长。血癌发生在人体的造血组织中，例如骨髓和淋巴系统。许多生活方式要素都会增加血癌的风险，包括吸烟、不良饮食、缺乏运动和饮酒过多。这些恶性会影响血球的生长和运作。由于人口变化、生活方式决定、环境暴露、遗传倾向和诊断方法改进等要素，这一领域正在不断扩大。

输血部门预计在预测期内年复合成长率最高

预计输血领域在预测期内年复合成长率最高。输血透过补充血球数量来增加血液中血红素的含量。输血可以提高身体为重要器官和组织提供氧气的能力。呼吸急促、虚弱和疲劳是可以透过输血缓解的一些症状。此外，输血对于维持接受积极治疗（例如血液恶性化疗）的患者至关重要。对于患有严重血液缺陷的人来说，输血可以缓解不适，提高生活质量，过着更积极的生活，并减轻症状。

比最大的地区

由于患者群体意识的提高，预计北美在预测期内将占据最大的市场占有率。医学研究和开发处于北美前沿。这包括配合措施发现新药、增强现有治疗方法和探索新想法。辉瑞（美国）和 Medexus 製药公司（加拿大）等主要公司正在向该地区扩张。血液疾病的高发生率、先进的医疗保健系统和蓬勃发展的製药部门是推动北美血液疾病市场的一些原因。

复合年复合成长率最高的地区：

预计亚太地区在预测期内年复合成长率最高。亚太地区人口多样化，具有不同的遗传倾向和环境因素，导致多种血液疾病。印度和东南亚国家等某些国家的地中海贫血和镰状细胞性贫血等遗传性血液疾病的发生率很高。日本和国外的製药公司正积极致力于血液疾病治疗方法、药物和药物的开发和普及。此外，主要企业和新兴製药公司和研究机构之间的频繁进步和合作正在推动该地区血液疾病市场的扩张。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球血液疾病市场：依类型

  • A型血友病
  • B型血友病
  • 血管性血友病
  • 其他类型

第6章全球血液疾病市场：依疾病分类

  • 遗传性血液疾病
  • 血红素紊乱
  • 骨髓增生性疾病
  • 血小板相关疾病
  • 血癌
  • 血浆病
  • 其他疾病

第7章全球血液疾病市场：依治疗类型

  • 药物治疗
    • 血浆衍生凝血因子浓缩物
    • 重组凝血因子浓缩物
    • 去氨加压素
    • 抗纤溶药
    • 纤维蛋白密封剂
  • 因子替代疗法
  • 荷尔蒙替代疗法
  • 输血
  • 管道分析

第8章全球血液疾病市场：按配销通路

  • 药局
  • 医院药房
  • 网路药房
  • 零售药房

第9章全球血液疾病市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Novo Nordisk A/S
  • Bayer AG
  • Sanofi
  • Octapharma AG
  • Pfizer Inc.
  • Grifols International SA
  • Medexus Pharma, Inc.
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • Baxter International Inc.
  • Takeda Pharmaceutical Company Limited
  • Thea Laboratories
  • Zydus Group
  • Wellona Pharma
  • Ferring Pharmaceuticals
  • Novartis AG
  • OASIS Medical
  • Bausch & Lomb Incorporated
  • Johnson & Johnson Services Inc.
  • Sun Pharmaceutical Industries Limited
Product Code: SMRC23933

According to Stratistics MRC, the Global Blood Disorders Market is accounted for $15.08 billion in 2023 and is expected to reach $26.73 billion by 2030 growing at a CAGR of 8.6% during the forecast period. Blood disorders are a group of medical conditions that affect the blood and its components. They are also known as hematologic disorders or haematological conditions. Some blood disorders are genetic and present from birth, while others can develop later in life due to various factors such as infections, autoimmune conditions, or exposure to certain toxins. Treatment options can range from medication and lifestyle changes to more intensive therapies.

According to the World Federation of Hemophilia Report, in the year 2017, worldwide around 315,423 people are affected by blood disorders. Among them approximately 196,706 people are living with Hemophilia, 76,144 people with von Willebrand disease (VWD) and 42,573 with other blood disorders.

Market Dynamics:

Driver:

Increasing clinical trials and R&D

Significant improvements in the diagnosis and management of blood diseases have been made as a result of the growing emphasis on clinical trials, research, and development. The development of more accurate and sensitive blood condition diagnostic tests is the result of research efforts. These tests enable quicker and more precise identification, allowing medical professionals to start treating patients earlier. The market expansion is being fuelled by the rising investment in clinical trials, research, and development for blood diseases, which is significantly improving patient outcomes.

Restraint:

Lack of standardized guidelines

The complexity and variability of blood diseases, the paucity of research on some subtypes, and the requirement for individualised treatment strategies are a few causes for the absence of standardised recommendations. It is frequently necessary for haematologists, oncologists, geneticists, and other healthcare experts to work together to treat blood diseases. Treatment strategies could alter as a result of coordinating care among these various experts. Along with this, the market's expansion is hampered by resource constraints and a lack of data on rare conditions.

Opportunity:

Rising awareness regarding blood disorders

As part of larger initiatives to improve healthcare systems and address health inequalities internationally, the increased knowledge of blood disorders in developing countries is an important step towards improving the health and well-being of those afflicted by these ailments. Increased awareness draws greater funding and attention to efforts to investigate and find treatments for blood illnesses. As a result, increased funding for research and development has driven awareness initiatives, which is boosting market demand.

Threat:

Inadequate reimbursement policies

Treatments for blood disorders include prohibitively costly, cutting-edge procedures like gene therapy and stem cell transplants. A multidisciplinary approach is frequently used to treat blood diseases, including input from haematologists, oncologists, geneticists, and other experts. In addition, factors including the limited market size, the complexity of the treatment plans, and the lack of competition cause government and commercial insurers to have constrained budgets, which may lead to reduced reimbursement rates. This issues are impeding the market demand.

COVID-19 Impact

The COVID-19 pandemic has had a significant impact on the blood disorders market. The pandemic has led to delays in routine medical appointments and diagnostic testing, which has led to delayed diagnoses and treatment of blood disorders. The pandemic has caused delays and shortages in the distribution of vital medications for blood disorders by upsetting the world's pharmaceutical and medical device supply chains.

The blood cancers segment is expected to be the largest during the forecast period

The blood cancers segment is estimated to have a lucrative growth. Blood cancers originate in the blood-forming tissues of the body, such as the bone marrow or lymphatic system. Blood cancer risk is enhanced by a number of lifestyle factors, including smoking, eating poorly, being inactive, and drinking too much alcohol. The growth and operation of blood cells are both impacted by these malignancies. The segment is expanding as a result of factors such as demographic shifts, lifestyle decisions, environmental exposures, genetic predispositions, and improvements in diagnostic methods.

The blood transfusions segment is expected to have the highest CAGR during the forecast period

The blood transfusions segment is anticipated to witness the highest CAGR growth during the forecast period. Blood transfusions increase the amount of haemoglobin in the blood by replenishing the blood cell count. The body's capacity to oxygenate essential organs and tissues is improved by transfusions. Shortness of breath, weakness, and fatigue are some of the symptoms that are lessened by doing this. Additionally, blood transfusions are essential in sustaining patients receiving aggressive therapies like chemotherapy for blood malignancies. For people with severe blood flaws, it can ease their discomfort and enhance their quality of life, enabling them to lead more active lives and have fewer symptoms.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the increasing awareness among the patient population. Research and development in biomedicine are at the forefront in North America. This involves initiatives to find novel medicines, enhance current therapies, and investigate fresh ideas. Major firms like Pfizer Inc. (U.S.) and Medexus Pharma, Inc. (Canada) are present in this region. The high frequency of blood diseases, an advanced healthcare system, and a thriving pharmaceutical sector are some of the reasons that are driving the market for blood disorders in North America.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The APAC region is home to a diverse population with varying genetic predispositions and environmental factors, leading to a wide range of blood disorders. Certain countries like India and some Southeast Asian nations, have higher incidences of genetic blood disorders like thalassemia and sickle cell anaemia. Pharmaceutical firms from both domestic and foreign markets are actively involved in the creation and dissemination of treatments, therapies, and drugs for blood diseases. Additionally, frequent advancements and partnerships between key players, as well as emerging pharmaceutical firms and research institutes, are fueling the Blood Disorders Market expansion in this region.

Key players in the market:

Some of the key players profiled in the Blood Disorders Market include: Novo Nordisk A/S, Bayer AG, Sanofi, Octapharma AG, Pfizer Inc., Grifols International SA, Medexus Pharma, Inc., CSL Limited, F. Hoffmann-La Roche Ltd., Baxter International Inc., Takeda Pharmaceutical Company Limited, Thea Laboratories, Zydus Group, Wellona Pharma, Ferring Pharmaceuticals, Novartis AG, OASIS Medical, Bausch & Lomb Incorporated, Johnson & Johnson Services Inc. and Sun Pharmaceutical Industries Limited.

Key Developments:

In October 2023, Sanofi announced that it has entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extra intestinal pathogenic E. coli (9-valent) developed by Janssen, currently in Phase 3.

In February 2023, A Johnson & Johnson drug for rare infant blood disorder achieves main goal of phase 2 test. The drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses.

Types Covered:

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Other Types

Disorders Covered:

  • Genetic Haematology Disorders
  • Haemoglobin Disorders
  • Myeloproliferative Disorders
  • Platelet Based Disorders
  • Blood Cancers
  • Plasma Disorders
  • Other Disorders

Treatment Types Covered:

  • Drug Therapy
  • Factor Replacement Therapy
  • Hormone Replacement Therapy
  • Blood Transfusions
  • Pipeline Analysis

Distribution Channels Covered:

  • Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Blood Disorders Market, By Type

  • 5.1 Introduction
  • 5.2 Hemophilia A
  • 5.3 Hemophilia B
  • 5.4 Von Willebrand Disease
  • 5.5 Other Types

6 Global Blood Disorders Market, By Disorder

  • 6.1 Introduction
  • 6.2 Genetic Haematology Disorders
  • 6.3 Haemoglobin Disorders
  • 6.4 Myeloproliferative Disorders
  • 6.5 Platelet Based Disorders
  • 6.6 Blood Cancers
  • 6.7 Plasma Disorders
  • 6.8 Other Disorders

7 Global Blood Disorders Market, By Treatment Type

  • 7.1 Introduction
  • 7.2 Drug Therapy
    • 7.2.1 Plasma-derived Coagulation Factor Concentrates
    • 7.2.2 Recombinant Coagulation Factor Concentrates
    • 7.2.3 Desmopressin
    • 7.2.4 Antifibrinolytics
    • 7.2.5 Fibrin sealants
  • 7.3 Factor Replacement Therapy
  • 7.4 Hormone Replacement Therapy
  • 7.5 Blood Transfusions
  • 7.6 Pipeline Analysis

8 Global Blood Disorders Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Drug Stores
  • 8.3 Hospital Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Retail Pharmacies

9 Global Blood Disorders Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Novo Nordisk A/S
  • 11.2 Bayer AG
  • 11.3 Sanofi
  • 11.4 Octapharma AG
  • 11.5 Pfizer Inc.
  • 11.6 Grifols International SA
  • 11.7 Medexus Pharma, Inc.
  • 11.8 CSL Limited
  • 11.9 F. Hoffmann-La Roche Ltd.
  • 11.10 Baxter International Inc.
  • 11.11 Takeda Pharmaceutical Company Limited
  • 11.12 Thea Laboratories
  • 11.13 Zydus Group
  • 11.14 Wellona Pharma
  • 11.15 Ferring Pharmaceuticals
  • 11.16 Novartis AG
  • 11.17 OASIS Medical
  • 11.18 Bausch & Lomb Incorporated
  • 11.19 Johnson & Johnson Services Inc.
  • 11.20 Sun Pharmaceutical Industries Limited

List of Tables

  • Table 1 Global Blood Disorders Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Blood Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Blood Disorders Market Outlook, By Hemophilia A (2021-2030) ($MN)
  • Table 4 Global Blood Disorders Market Outlook, By Hemophilia B (2021-2030) ($MN)
  • Table 5 Global Blood Disorders Market Outlook, By Von Willebrand Disease (2021-2030) ($MN)
  • Table 6 Global Blood Disorders Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 7 Global Blood Disorders Market Outlook, By Disorder (2021-2030) ($MN)
  • Table 8 Global Blood Disorders Market Outlook, By Genetic Haematology Disorders (2021-2030) ($MN)
  • Table 9 Global Blood Disorders Market Outlook, By Haemoglobin Disorders (2021-2030) ($MN)
  • Table 10 Global Blood Disorders Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 11 Global Blood Disorders Market Outlook, By Platelet Based Disorders (2021-2030) ($MN)
  • Table 12 Global Blood Disorders Market Outlook, By Blood Cancers (2021-2030) ($MN)
  • Table 13 Global Blood Disorders Market Outlook, By Plasma Disorders (2021-2030) ($MN)
  • Table 14 Global Blood Disorders Market Outlook, By Other Disorders (2021-2030) ($MN)
  • Table 15 Global Blood Disorders Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 16 Global Blood Disorders Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 17 Global Blood Disorders Market Outlook, By Plasma-derived Coagulation Factor Concentrates (2021-2030) ($MN)
  • Table 18 Global Blood Disorders Market Outlook, By Recombinant Coagulation Factor Concentrates (2021-2030) ($MN)
  • Table 19 Global Blood Disorders Market Outlook, By Desmopressin (2021-2030) ($MN)
  • Table 20 Global Blood Disorders Market Outlook, By Antifibrinolytics (2021-2030) ($MN)
  • Table 21 Global Blood Disorders Market Outlook, By Fibrin sealants (2021-2030) ($MN)
  • Table 22 Global Blood Disorders Market Outlook, By Factor Replacement Therapy (2021-2030) ($MN)
  • Table 23 Global Blood Disorders Market Outlook, By Hormone Replacement Therapy (2021-2030) ($MN)
  • Table 24 Global Blood Disorders Market Outlook, By Blood Transfusions (2021-2030) ($MN)
  • Table 25 Global Blood Disorders Market Outlook, By Pipeline Analysis (2021-2030) ($MN)
  • Table 26 Global Blood Disorders Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 27 Global Blood Disorders Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 28 Global Blood Disorders Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 29 Global Blood Disorders Market Outlook, By Online Pharmacies (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.